Study of families with suspected RUNX1 gene changes
Part of Blood & lymphatic, Cancer clinical trials.
This study follows people who have a known or suspected RUNX1 gene variant linked to FPDMM-like features. It may help improve understanding of the gene, and participants may contribute samples that researchers use for genetic testing and research.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your doctor) suspect a RUNX1 gene variant tied to FPDMM-like symptoms
- You may need to join through record review or a brief screening questionnaire
- If you have not had RUNX1 testing yet, or prior testing was negative, you may still qualify
- You can join at any age and for any sex
- Family members who are not affected may be invited to provide samples for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with a specific genetic change (RUNX1 mutation) that increases the risk of blood cancers. It tests whether a stem cell transplant from a half-matched family member can help treat or cure these blood conditions.
This trial tests if imatinib can help people with a genetic condition called RUNX1 deficiency, which causes bleeding problems. It aims to increase the activity of the RUNX1 gene to improve blood clotting.
This study looks at people and families who have changes in the DDX41 gene or similar genes that may increase the risk of cancer. By joining, you can help researchers learn more about these gene changes and how they affect health.
This trial tests whether a low dose of sirolimus, a drug that calms the immune system, can help improve blood counts and reduce bleeding risk in people with a genetic condition called RUNX1 familial platelet disorder. If it works, it might lower the chance of developing serious blood problems later.
This study tests the safety of collecting your own blood stem cells (called CD34+ cells) using a process called apheresis. It is for people with RUNX1 familial platelet disorder who may need a stem cell transplant in the future.
This trial tests a low dose of sirolimus, a medicine that may help your bone marrow make more blood cells, especially platelets. It is for people with a specific genetic change (RUNX1) that affects blood cell production.
Hear when a new Rare Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.